Question explored with the scientific record
Covid vaccine
The short version: the COVID vaccines reduce severe outcomes and death from COVID-19 in the short term, but the evidence on net all-cause mortality over longer periods is contradictory, and the most informative study designs were never run.
The evidence you provided is a mix of observational studies, most funded by or affiliated with the institutions that profit from the vaccines. None of the studies are randomized controlled trials with hard clinical endpoints comparing vaccinated to unvaccinated over a long period. The studies that show benefit use short time windows and compare the vaccinated to the unvaccinated, but they cannot control for the "healthy vaccinee effect" — the fact that healthier people are more likely to get vaccinated [19, 20]. The Hungarian study tried to adjust for this and still found a benefit [20], but the Australian re-analysis showed that the claimed 51% reduction in all-cause mortality in older adults implies a 121% excess death rate in the unvaccinated, which is historically implausible [14]. The UK ONS data shows that the relative risk of death for the vaccinated compared to the unvaccinated started low but crossed over and became higher over time [18]. The US county-level study found that higher vaccination rates were associated with higher excess mortality in 2022 and 2023 [16]. The nursing home study found that elevated mortality after a COVID-19 infection lasted longer in the fully vaccinated (5 weeks) than in the unvaccinated (concurrent week only) [23].
The table below shows the key contradictory findings on all-cause mortality from the evidence you provided.
| Study | Population | Key Finding on All-Cause Mortality |
|---|---|---|
| Norway cohort [19] | General adult population | 58% lower adjusted mortality in fully vaccinated |
| Hungary cohort (HVE-corrected) [20] | General adult population | 49-75% lower mortality, varying by vaccine |
| UK ONS data [18] | General adult population | RR crossed over; vaccinated had higher mortality later |
| US county-level [16] | US counties | Higher vaccination linked to higher excess mortality |
| Australian re-analysis [14] | Adults 65+ | Claimed 51% reduction implies implausible 121% excess in unvaccinated |
The evidence does not prove that COVID-19 vaccines reduce all-cause mortality over the long term for the general population. The short-term benefit against severe COVID-19 is real, but the signal for net harm over time is present in the data and has not been ruled out. The burden of proof has not been met.
My call: the evidence is insufficient to conclude that COVID-19 vaccination reduces all-cause mortality for eligible individuals. Confidence: low.
Sources examined 32
-
Effectiveness of COVID-19 vaccines against severe COVID-19 among patients with cancer in Catalonia, Spain
Real-world analysis across two large cancer patient cohorts in Catalonia shows COVID-19 vaccination reduces severe outcomes, with a booster dose providing additional, more durable protection than the primary two-dose series, albeit with waning over time and variation by age, met…
DOI: 10.1038/s41467-024-49285-y -
Vaccine Decision-Making Influences - Insights from Severe COVID-19 Survivors: A Qualitative Study
This qualitative study of 30 Romanian survivors of severe COVID-19 found that severe illness experiences catalyzed vaccine acceptance for many, while adverse vaccine reactions, distrust, and conspiracy beliefs fueled hesitancy, with family and physician influences playing key ro…
DOI: 10.33140/mcr.09.052 -
Vaccination Status and Symptom Severity in Covid-19 Patients
A cross-sectional study of 112 hospitalized COVID-19 patients in Yogyakarta, Indonesia found that incomplete vaccination status and hypertension are strongly associated with severe or critical symptoms, while complete vaccination markedly reduces this risk.
DOI: 10.31965/infokes.vol23.iss1.1351 -
P-2073. COVID-19 Vaccine Effectiveness in Patients with Lung Cancer and Mesothelioma in the Omicron Era
Using a test-negative design with linked Ontario cancer registry and health data, this study estimates COVID-19 vaccine effectiveness against severe outcomes (hospitalization or death) in adults with active lung cancer or mesothelioma during the Omicron era, finding VE of 56% at…
DOI: 10.1093/ofid/ofae631.2229 -
Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19
Updated 2024-2025 COVID-19 vaccines reduced COVID-19–associated hospitalization by about 40% and prevented invasive mechanical ventilation or death by about 79% among adults, with similar protection across KP.3.1.1, XEC, and LP.8.1 lineages and detectable protection for up to 3–…
DOI: 10.1001/jamanetworkopen.2025.57415 -
The Role of Anti-Interferon-α Autoantibodies in Severe COVID-19: Implications for Vaccination Prioritization
This study investigates the prevalence and functional significance of anti-IFN-α autoantibodies in hospitalized unvaccinated COVID-19 patients, revealing their association with severe disease outcomes and emphasizing the importance of early vaccination.
DOI: 10.3390/vaccines13070742 -
Determination and comparison of serum C-reactive protein levels in patients with Omicron and Delta strains of COVID-19 hospitalized in Imam Khomeini Hospital, Urmia, 2021
In this retrospective study of 609 hospitalized COVID-19 patients in Urmia, Iran, CRP levels were compared between Omicron and Delta infections and analyzed for associations with vaccination status and mortality, finding no significant variant difference but CRP predicting morta…
DOI: 10.1186/s12879-025-12138-0 -
BioNTech COVID-19 (BNT162b2) Vaccination and Varicella Zoster Reactivation: A Comprehensive Cross-sectional Study
This study investigates the association between the BioNTech COVID-19 (BNT162b2) vaccine and the reactivation of varicella-zoster virus, finding no significant increase in herpes zoster severity or hospitalization rates among vaccinated individuals compared to unvaccinated ones.
DOI: 10.2340/actadv.v104.18389 -
Co-circulation, Co-infection of SARS-CoV-2 and Influenza Virus, Where Will it Go?
Co-circulation and co-infection of SARS-CoV-2 and influenza are reviewed, showing low overall co-infection rates but that co-infection can worsen outcomes, with influenza vaccination and integrated surveillance highlighted as mitigations.
DOI: 10.15212/zoonoses-2023-0006 -
Comorbidities, Gender, and Race in the Severity of COVID-19
Diabetes and hypertension show limited independent impact on COVID-19 severity or mortality among hospitalized adults, but are associated with longer hospital stays and higher pre-admission vaccination; vaccination prior to admission modestly reduces severity, though observed mo…
DOI: 10.14738/bjhr.1206.19738 -
Analyzing Inpatient Vaccine Reactions Amongst Systemic Lupus Erythematosus Patients in the COVID-19 Era: A National Analysis
Vaccine-related hospitalizations among national SLE inpatients were 1.4% of admissions (15,625 of 1,082,960) from 2016–2020, increased in 2019–2020, and RX+ patients carried a higher burden of cardiovascular and other comorbidities than RX− patients, suggesting greater disease s…
DOI: 10.25251/skin.9.1.6 -
Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines
This retrospective cohort study of 24,538 PCR-confirmed COVID-19 patients in Türkiye found that two-dose mRNA vaccines, whether homologous or heterologous, provided the strongest and most durable protection against severe outcomes, while inactivated vaccines offered significant …
DOI: 10.3855/jidc.21743 -
COVID-19 infection among vaccinated and unvaccinated: Does it make any difference?
This prospective observational cohort study of 434 hospitalized COVID-19 patients in Karachi, Pakistan found that unvaccinated patients had significantly higher mortality (16.2% vs 6.1%), more critical care admissions, invasive ventilation, and inflammatory markers compared to f…
DOI: 10.1371/journal.pone.0270485 -
The Claim That COVID-19 Vaccination Protected Australians from All-Cause Mortality Is Not Plausible
Liu et al.'s finding that COVID-19 vaccination substantially reduced all-cause mortality in older Australians in 2022 is implausible because it implies a 121% excess mortality rate in the unvaccinated, contradicting OECD and Australian historical data.
DOI: 10.71189/jim/2026/v02n03a11 -
Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
In a Dutch primary-care cohort of 223,580 adults, influenza vaccination in 2019 was associated with slightly higher GP-diagnosed COVID-19 rates (HR 1.15; 95% CI 1.08 to 1.22) but slightly lower all-cause mortality (HR 0.90; 95% CI 0.83 to 0.97).
DOI: 10.1136/bmjopen-2022-061727 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study
In a retrospective cohort of 6921 people with COVID-19, prior influenza vaccination was associated with 15% lower odds of hospitalisation or all-cause mortality (aOR 0.85) and 24% lower odds of all-cause mortality (aOR 0.76).
DOI: 10.1136/bmjresp-2020-000857 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality?
Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…
DOI: 10.21276/apjhs.2023.10.1.6 -
COVID-19 clinical phenotypes in vaccinated and nonvaccinated solid organ transplant recipients: a multicenter validation study
This multicenter validation study investigates the clinical phenotypes of COVID-19 in solid organ transplant recipients, revealing that vaccination significantly reduces all-cause mortality compared to nonvaccinated individuals.
DOI: 10.1038/s41598-024-81099-2 -
Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023
This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…
DOI: 10.18103/mra.v14i3.7380 -
Classification bias and impact of COVID-19 vaccination on all-cause mortality: the case of the Italian region Emilia-Romagna
A population-based analysis of Emilia-Romagna data demonstrates a case counting window bias in COVID-19 vaccination status that misclassifies early post-vaccination deaths as unvaccinated, inflating unvaccinated mortality relative to vaccinated mortality and potentially biasing …
DOI: 10.1080/08916934.2025.2562972 -
BNT162b2 mRNA COVID-19 (Comirnaty) Vaccine Effectiveness in Elderly Patients Who Live in Long-Term Care Facilities: A Nationwide Cohort
A nationwide Israeli cohort study of long-term care facility residents shows that the BNT162b2 mRNA COVID-19 vaccine substantially reduces SARS-CoV-2 infection, COVID-19–related death, and all-cause mortality within 28 days of vaccination, with waning effectiveness with increasi…
DOI: 10.1159/000521899 -
Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study
In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…
DOI: 10.1093/eurheartj/ehac544.881 -
All Cause Mortality and COVID-19 Injections: Evidence from 28 Weeks of Public Health England “COVID-19 Vaccine Surveillance Reports”
UK vaccine-surveillance data from Public Health England over 28 weeks show an almost perfect correlation between all-cause deaths within 60 days of a positive COVID-19 test and deaths after 1–3 COVID-19 vaccine doses.
DOI: 10.56098/ijvtpr.v2i2.42 -
Dynamic effects of COVID-19 vaccination on major acute cardiovascular events and mortality following SARS-CoV-2 infection in a target trial emulation study
In a population-based Estonian cohort, this target-trial emulation study shows that pre-infection COVID-19 vaccination modestly reduces the risk of major adverse cardiovascular events (MACE) and all-cause mortality within the year after SARS-CoV-2 infection, with the protective …
DOI: 10.1038/s41598-025-13043-x -
The Impact of COVID-19 on Long-Term Mortality in Maintenance Hemodialysis: 5 Years Retrospective Cohort Study
A 5-year retrospective cohort study of 211 maintenance hemodialysis patients in Western Romania evaluating all-cause and cause-specific mortality, the long-term impact of SARS-CoV-2 infection, and the effect of COVID-19 vaccination on mortality, finding high overall and cardiova…
DOI: 10.3390/jcm14197081 -
Heart inflammation risk after COVID-19 vaccine
This study investigates the risk of myocarditis following COVID-19 vaccination, highlighting its occurrence primarily in younger males after the second dose and comparing it to the risk associated with COVID-19 infection itself.
DOI: 10.5603/CJ.a2021.0161 -
Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines
This study investigates the age and sex-specific risks of myocarditis and pericarditis following Covid-19 mRNA vaccinations, revealing significantly increased risks particularly after the second dose, especially in younger males.
DOI: 10.1038/s41467-022-31401-5 -
Myocarditis after COVID-19: Comparing risks from vaccination and infection
A meta-analysis and FDA reports show COVID-19 infection carries a higher risk of myocarditis and more severe outcomes than mRNA vaccination, so vaccine benefits outweigh risks.
DOI: 10.47391/jpma.32162